Clinical Trial Search

Primary: Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs) — 7; 3; 7; 3 Participants

Primary: Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug — 0; 0; 0; 0 participants

Primary: Change From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 Hours — -1.56; -1.76; -1.55; -1.78 log10 copies per mL

Primary: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts. — 0; 0; 0; 3 Participants

Primary: Treatment-Emergent Adverse Events — 3; 12; 3; 11 Participants

Primary: Pilot Phase: Tumour Levels of Irinotecan and SN-38 at Cycle 1 Day 4 — 4253; 38.1 nanograms per gram (ng/g)

Primary: Visual Acuity (VA) — 19.9; 19.83 score on a scale — p=0.890

Primary: Number of Adverse Events (EAS) — 11; 10 adverse events — p=0.749

Primary: Pharmacokinetic (PK) Parameter: AUClast of Lanraplenib Presented Based on Range of CLcr — 2317.8; 2027.4; 2076.3; 1871.6 h*ng/mL

Primary: Global Longitudinal Strain — 19.2; -19.6; 21.4; -21.5 % deformation

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE…

Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants

Primary: Recommended Phase 2 Dose of LY3164530: Maximum Tolerated Dose (MTD) — 1000; 500 milligrams (mg)

Primary: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs — 2; 3; 4; 6 Participants

Primary: AUClast of Plasma Budesonide (VR647 Inhalation Suspension Delivered by the VR647 Inhalation System or Pulmicort Respules Delivered by a Conventional Jet Nebulizer)…